نتایج جستجو برای: telaprevir

تعداد نتایج: 686  

Journal: :Hepatology 2012
Douglas Dieterich

These are extraordinary times in the history of HCV drug development. We waited 13 years between the approval of ribavirin in 1998 and the approval of telaprevir and boceprevir in 2011. The trajectory of drug discovery and clinical trials has gone from exponential to warp speed since the EASL meeting in April 2011, and these two articles are perfect examples of what has changed the world of hep...

Journal: :The New England journal of medicine 2011
Kenneth E Sherman Steven L Flamm Nezam H Afdhal David R Nelson Mark S Sulkowski Gregory T Everson Michael W Fried Michael Adler Hendrik W Reesink Marie Martin Abdul J Sankoh Nathalie Adda Robert S Kauffman Shelley George Christopher I Wright Fred Poordad

BACKGROUND Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of peginterferon-ribavirin treatment for a sustained virologic response. We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations. METHODS We enrolled patients with chronic infection w...

2015
C Laouénan J Guedj G Peytavin TH Tram Nguyen M Lapalus F Khelifa-Mouri N Boyer F Zoulim L Serfaty J-P Bronowicki M Martinot-Peignoux O Lada T Asselah C Dorival C Hézode F Carrat F Nicot P Marcellin F Mentré

Hézode et al. recently reported the frequent occurrence of anemia and thrombocytopenia in the ANRS-CO20-CUPIC cohort of hepatitis C virus (HCV) cirrhotic experienced patients treated with pegylated-interferon (Peg-IFN), ribavirin (RBV), and telaprevir or boceprevir.1,2 Using frequent measurements of serum drug concentrations, hemoglobin, and platelet concentrations obtained in 15 patients of th...

2014
Christian M Lange Ira M Jacobson Charles M Rice Stefan Zeuzem

Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon‐α monotherapy in 1992 to the approval of telaprevir‐ and boceprevir‐based triple therapies with pegylated interferon‐α and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%. Significant further improveme...

2016
Pejman Solaimani Christopher Hogan Matthew Chin Juan L Miranda Douglas L Nguyen

With 5.2 million people living with Hepatitis C, it is the most common blood-borne infection in the United States. Untreated chronic HCV infection may result in adverse consequences such as cirrhosis, portal hypertension, hepatic failure and hepatocellular carcinoma. Previously approved treatments include Pegylated-interferon alpha-2a/2b plus ribavirin, Boceprevir and Telaprevir. Recently appro...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید